---
layout: default
title: Palivizumab
parent: 僅模型預測 (L5)
nav_order: 262
evidence_level: L5
indication_count: 10
---

# Palivizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Palivizumab: From RSV Prophylaxis to Benign Neoplasm of Tongue

## One-Sentence Summary

> Palivizumab is a monoclonal antibody targeting the RSV F protein, used for respiratory syncytial virus (RSV) prophylaxis in high-risk infants.
> The TxGNN model predicts a possible association with **Benign Neoplasm of Tongue**,
> but this prediction is currently supported by **0 clinical trials** and **0 publications**, with no plausible mechanistic rationale identified.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | RSV (Respiratory Syncytial Virus) infection prophylaxis — referenced in evidence pack rationale text; not formally recorded in Norway regulatory filings |
| Predicted New Indication | Benign neoplasm of tongue |
| TxGNN Prediction Score | 99.94% (rank 923 of full candidate list) |
| Evidence Level | L5 |
| Norway Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is currently not available for palivizumab in this evidence pack. Based on the evidence pack's own annotations, palivizumab is an RSV F-protein–targeting monoclonal antibody, used to prevent RSV infection in vulnerable pediatric populations.

The top 10 TxGNN-predicted indications for this drug — benign neoplasm of tongue, epiglottis neoplasm, cervical neuroblastoma, hypopharyngeal neoplasm, floor-of-mouth neoplasm, testicular tumor, cystic neoplasm, jugular foramen schwannoma, mesenchymoma, and thyroglossal duct cyst — span an unrelated mix of benign and malignant neoplasms across disparate anatomical sites and tissue origins (epithelial, neural crest, mesenchymal, and developmental/congenital).

The evidence pack's own repurposing rationale explicitly states, for every one of these top 10 candidates, that there is **no known mechanistic link** between an antiviral neutralizing antibody and neoplastic disease processes. This pattern — a cluster of biologically unrelated, low-prevalence, and mechanistically disconnected diseases all scoring near the top of the model's global rank (though still relatively deep at rank ~920–970) — is consistent with a modeling artifact rather than a genuine repurposing signal. No indication in this set warrants further investigation without independent supporting evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Norway Market Information

Palivizumab is not marketed in Norway per this evidence pack (market status: not marketed; 0 authorizations on file). No product license records are available to summarize.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Key warnings, contraindications, and drug interaction data are not currently available in the evidence pack. Note: TFDA/label warning and contraindication data is flagged as a **Blocking** data gap (DG001) for safety review purposes.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All top 10 TxGNN-predicted indications for palivizumab are rated L5 (model prediction only), with zero supporting clinical trials or literature, and the evidence pack itself documents no plausible mechanistic connection between an RSV-neutralizing antibody and any of the predicted neoplastic conditions. There is no basis to advance any candidate indication at this time.

**To proceed, the following is needed:**
- Resolve DG001 (Blocking): TFDA/local label warnings and contraindications, required before any S1 safety screening can occur
- Resolve DG002 (High): Confirmed mechanism of action data from DrugBank, needed to evaluate mechanistic plausibility of any future candidate
- Independent literature or preclinical search specifically targeting palivizumab and oncology/neoplasm pathways, to confirm whether the current top-10 list reflects a genuine signal or a model artifact
- If no supporting evidence emerges, consider deprioritizing this drug-indication cluster in future TxGNN evidence pack refresh cycles
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

